Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia

Chest

Volumn 115, Issue 6, 1999, Pages 1616-1620

  Tardy Poncet, Brigitte ^a   Tardy, Bernard ^a   Reynaud, Jacqueline ^a   Mahul, Philippe ^a   Mismetti, Patrick ^a   Mazet, Eliane ^a   Guyotat, Denis ^a  

^a HÔPITAL NORD   (France)

Author keywords

Heparin; Thrombocytopenia; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 9A; DANAPAROID; HEPARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0032994196     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.6.1616     Document Type: Article

References (17)

1. 1 Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
2. 2 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemostasis Thromb 1991; 10:1-34
3. 3 Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73:1592-1596
4. 4 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992; 67:545-549
5. 5 Warkentin TE, Russett JI, Johnston M, et al. Warfarin treatment of deep vein thrombosis complicating heparin-induced thrombocytopenia is a risk factor for initiation of venous limb gangrene: report of nine patients implicating the interacting procoagulant effects of two anticoagulant agents [abstract]. Thromb Haemost 1995; 73:1110
6. 6 Chong BH, Magnani HN. Danaparoid sodium in heparin-induced thrombocytopenia. Hemostasis 1992; 22:85-91
7. 7 Nurmohamed MT, Fareed J, Hoppensteadt D, et al. Pharmacological and clinical studies with Lomoparan, a low-molecular-weight glycoaminoglycan. Semin Thromb Hemost 1991; 17:205-213
8. 8 De Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thrombo-embolism: a randomized controlled trial. Ann Intern Med 1995; 123:1-9
9. 9 Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34:381-385
10. 10 Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68:95-96
11. 11 Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPSII) based on a European/North American multicenter study. JAMA 1993; 270:2957-2963
12. 12 Tardy-Poncet B, Mahul P, Beraud AM, et al. Failure of danaparoid sodium therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br J Haematol 1995; 90:969-973
13. 13 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100:535-540
14. 14 Magnani HN. Heparin-induced thrombocytopenia: an overview of 230 patients treated with danaparoid sodium. Thromb Haemost 1993; 70:554-561
15. 15 Boon DMS, Michiels JJ, Stibbe M, et al. Heparin -induced thrombocytopenia and antithrombotic therapy [letter]. Lancet 1994; 344:1296
16. 16 Boshkov LK, Warkentin TE, Haymard CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84:322-328
17. 17 Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83:1535-1541